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Abstract 
Eicosanoids are the major metabolites of fatty acids and they are correlated with many kinds of 
diseases such as Alzheimer’s, cancer and cardiovascular diseases. Usually, most of the eicosanoids 
derived from ω-6 fatty acids have pro-inflammatory properties while those from ω-3 fatty acids are 
anti-inflammatory. The type and amount of the production of eicosanoids are affected by many 
factors including availability of fatty acids, activity of cyclo- and lipo- oxygenase and type of cells.  
In this thesis, a solid-phase extraction method combined with HPLC-MS/MS is first developed 
to analyze simultaneously PGE2, PGE3, LTB4, 6-keto-PGF1α, Δ17-6-keto-PGF1α, RvD1 and RvD2 in 
two types of cell culture medium, specifically EBM-2 medium and cL-15 medium. This method is 
systematically optimized and validated. The concentrations of internal standards are determined by a 
Doehlert design to keep the response factors constant in the analytical range. Method validation for 
the various eicosanoids in EBM-2 medium shows limits of quantification (LOQ) between 0.1-0.6 
ng/ml, recovery between 57.1-127.2% and precision between 0.2- 20.7%. For cL-15 medium, LOQ 
is between 0.1-8 ng/ml, recovery 63.9-125.7% and precision 3.5-30.7% for the analyzed eicosanoids.  
The validated method is then applied to investigate the effect of fatty acids on the production of 
eicosanoids in fish liver cells, fish head kidney cells and human umbilical vein endothelial cells 
(HUVEC). The various types of cells are incubated in medium with different combination of fatty 
acids according to a 2
4
-factorial design and eicosanoids in the medium are analyzed after 24 hours. 
The results reveal that RvD1 and RvD2 cannot be detected in any type of cells. Addition of 
arachidonic acid (AA) increases the productions of all the other five eicosanoids except in fish head 
kidney cells where production of PGE3 is reduced in a small degree. Individual linoleic acid (LA) 
reduces the productions of 6-keto-PGF1α and Δ17-6-keto-PGF1α and increases the production of PGE3 
in both types of fish cells. Eicosapentaenoic acid (EPA) remarkably increases the production of LTB4 
and docosahexaenoic acid (DHA) decreases the production of Δ17-6-keto-PGF1α in three types of 
cells. The effects of interactions are complex and most of them are different in different types of 
cells.  
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1. Introduction 
1.1 Fatty acids 
1.1.1 Classification of the fatty acids 
Fatty acids are carboxylic acids with an aliphatic chain. In nature, most of the fatty acids have an 
even number of carbon atoms, from 4 to 28. According to the length of the aliphatic chain, fatty acids 
can be categorized to short-chain fatty acids, medium-chain fatty acids, long-chain fatty acids and 
very long-chain fatty acids. A short-chain fatty acid has an aliphatic chain with less than 6 carbon 
atoms, a medium-chain has 6-12 carbons, a long-chain has 13-21 carbons, and a very long-chain 
fatty acid has more than 22 carbons. Besides, the aliphatic chain can be saturated or unsaturated, 
which divides the fatty acids into two classes: saturated and unsaturated fatty acids. Unsaturated fatty 
acids can be further classed to monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids 
(PUFAs) according to the number of the double bounds. All of the fatty acids, especially PUFAs, are 
very important for the development and function of human and animal organisms. 
1.1.2 Nomenclature of the unsaturated fatty acids 
All of the fatty acids have their trivial names, systematic names defined by the International 
Union of Pure and Applied Chemistry (IUPAC) and symbol names. Since symbols are short and 
helpful for understanding the chemical structure of the fatty acids, they are widely applied names in 
scientific and popular literature. 
A symbol name contains the number of carbon atoms, the number of double bounds and the 
position of the first double bound. To understand the position of the double bounds, the numbering of 
the carbon atoms should be first introduced. The carbons labelled as ω or n are those where the 
methyl group is numbered as carbon one. For example, linoleic acid (LA, 18:2n-6) has 18 carbons, 
two double bonds and the first double bound locates between the 6th and 7th carbons from the 
methyl end, so it is designated an n-6 (or ω-6) fatty acid, and the symbol name is 18:2n-6. More 
examples can be seen in Figure 1.1. 
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Figure 1.1 Chemical structures of five important fatty acids 
 
1.1.3 Polyunsaturated fatty acids 
PUFAs are the fatty acids that have more than one double bond in the aliphatic chain. Recently, 
dietary PUFAs are drawing more and more attention worldwide since they are correlated with many 
kinds of diseases. ω-3 and ω-6 fatty acids are two kinds of PUFAs. They cannot be synthesized by 
mammals, and so they must be obtained from the diet. Thus, the effect of different ω-3 and ω-6 fatty 
acids are becoming much more important.  
Linoleic (LA, 18:2n-6) and α-linolenic (α-LNA, 18:3n-3) acids are the representative of ω-6 and 
ω-3 fatty acids respectively. They are the starting point to manufacture other ω-6 and ω-3 series fatty 
acids. LA can be metabolized to arachidonic acid (AA, 20:4n-6) by desaturase and elongase, while 
α-LNA is the precursor of the eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 
22:6n-3). In addition to the conversion from EPA to DHA, DHA can be reconverted to EPA also. The 
metabolism of different fatty acids is shown in Figure 1.2. It is worth noting that LA and α-LNA are 
involved in the similar metabolic system, so there is competition between them. Since α-LNA has a 
higher affinity for the enzymes involved in metabolism compared with LA, the recommendation 
ratio between LA and α-LNA is between 4/1 to 10/11.  
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1.2 Eicosanoids 
1.2.1 Production of eicosanoids 
One of the most important functions of PUFAs is related to their enzymatic conversion into 
eicosanoids. PUFAs are first released from membrane phospholipids by the action of various 
phospholipases. Then, they are metabolized to different eicosanoids. AA is the substrate for two 
classes of enzymes, cyclooxygenases (COX) which produce 2-series prostaglandins, 2-series 
prostacyclins and 2-series thromboxanes, and lipooxygenases (LOX) which catalyze the biosynthesis 
of hydroxyeicosatetraenoic acids (HETEs) and 4-series leokotrienes. EPA exhibits a similar 
metabolism to AA, but it is metabolized to 3-series prostaglandins, 3-series thromboxanes from COX 
and 5-series leokotrienes and hydroxyeicosapentaenoic acids from LOX. DHA are mainly converted 
to D-series resolvins by LOX. The metabolism of PUFAs is shown in Figure 1.2. 
 
 
Figure1.2 The metabolism of different PUFAs into eicosanoids
2
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1.2.2 Chemical structure of eicosanoids 
The chemical structures of the seven eicosanoids analyzed in this thesis and their corresponding 
internal standards are shown in Figure 1.3. 
  
PGE2 (C20H32O5, M=352.5） 
 
PGE3 (C20H30O5, M=350,5） 
 
 
 
PGE2-d4 (C20H28D4O5, M=356.5) 
 
LTB4 (C20H32O4, M=336.5) 
 
  
 
LTB4-d4 (C20H28D4O4, M=340.5) 
 
6-keto-PGF1α (C20H34O6, M=370.5) 
 
 
 
 
Δ17-6-keto-PGF1α (C20H32O6, M=368.5) 6-keto-PGF1α-d4 (C20H30D4O6, M=374.5) 
Figure 1.3-1 Chemical structures of different eicosanoids and associated internal standards 
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RvD1 (C22H32O5, M=376.5) 
 
RvD2 (C22H32O5, M=376.5) 
 
 
 
RvD2-d5 (C22H27D5O5, M=381.5) 
 
 
Figure 1.3-2 Chemical structures of different eicosanoids and associated internal standards 
1.2.3 Importance of eicosanoids 
Generally, AA-derived eicosanoids have pro-inflammatory effects and they are positively linked 
to arthritis
3
 and periodontal disease
4
 and also some disease which are not considered to be of 
inflammatory etiology such as Alzheimer’s disease5, cardiovascular disease2 and cancer6,7. In 
contrast, eicosanoids derived from ω-3 fatty acids have anti-inflammatory effects and they can 
inhibit the release of AA-derived eicosanoids. Resolvins is a new family of lipid mediators which 
possess both potent anti-inflammatory and immune-regulatory properties
8
. 
1.3 Cell culture 
Culturing cells is a process where cells are isolated from plants or animals and cultivated in a 
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medium with appropriate nutrients and conditions.  This technique became common in the 19
th
 
century
9
 and nowadays, has enabled us to investigate the effect of different drugs or compounds on 
cells, to synthesize valuable biological substances and to study the biochemistry of cells. Hence, they 
are becoming suitable substitute methods for animal experiments. Compared to other biological 
samples (i.e. plasma, urine, tissue), the physical-chemical conditions (pH, temperature, O2 and CO2 
tension) of the cell cultures are easily controlled which lead to the high consistency and 
reproducibility of the results. Thus, cell cultures are becoming the preferred techniques among 
researchers. 
1.4 Analytical method 
1.4.1 Instrumental techniques 
Different techniques have been used for eicosanoids analysis. Figure 1.4 and Table 1.1 show a 
chronological overview of the application of different instrumental techniques for the analysis of eicosanoids 
in cell cultures. 
Enzyme immunoassay (EIA) and radioimmunoassay (RIA) are two types of immunoassay 
methods. EIA carries out the quantitative analysis based on the color change caused by linking 
enzyme to antibody or antigen, while RIA based on the radioactivity resulting from the competition 
between radiolabeled and unlabeled antigens in an antigen-antibody reaction. Nowadays, EIA and 
RIA are easy to perform due to the availability of commercial kits. However, their main drawbacks 
are the involvement of dangerous radioactive substances in RIA, the overestimation of the analytical 
concentrations due to cross-reactivity and the detection of a single analyte per commercial kit. 
Gas chromatography (GC) is a powerful separation technique. Various volatile compounds can 
be separated in a GC column, identified by different detectors such as flame ionization detector (FID) 
or mass spectrometry (MS) and quantified by using appropriate standard compounds. This technique 
is highly sensitive. However, its major disadvantage is that it is limited to volatile compounds which 
are generally synthesized by time-consuming derivatization process. 
High-performance liquid chromatography (HPLC) largely extends the range of analytes. It is not 
only useful for volatile but also for non-volatile compounds. The traditional detectors for HPLC are 
UV-visible detector and diode array detector (DAD). The identification is made according the 
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spectrum and quantification based on the relationship between the absorption of light by the 
molecules of interest (e.g. absorbance) and the properties of these molecules (e.g. concentration). 
The main disadvantage of HPLC coupled to UV or DAD detectors is that the exact identification of 
compounds from the same category or family exhibiting same spectrum becomes expensive due to 
the need of several standards to achieve a reliable and positive identification.  
 
Table 1.1 Overview of the application of different instrumental techniques for the analysis of eicosanoids in 
cell cultures 
Year RIA EIA GC HPLC HPLC-MS Ref. 
1980   1   
10
 
1981       
1982    1  
11
 
1983 1     
12
 
1984    1  
13
 
1985 1     
14
 
1986 3  1 2  
15-20
 
1987 3   5  
21-26
 
1988 5   4  
27-35
 
1989 3 1    
36-39
 
1990 2 1    
40-42
 
1991 1  1 3  
43-46
 
1992 6 1 2 6  
47-56
 
1993 2 1 2 7  
57-67
 
1994 6 1 1 7  
68-78
 
1995 2   2  
79-82
 
1996 1 1 1 4  
83-88
 
1997 4 4  5  
89-98
 
1998 1 2  4 2 
99-105
 
1999 2 1 1 4  
106-111
 
2000 2 1 1 5  
112-119
 
2001  1  1 2 
120-123
 
2002 1 1 2 3 3 
124-132
 
2003 1 3  1 1 
133-138
 
2004  2  1 1 
139-142
 
2005  4 2 3 3 
143-154
 
2006    1 1 
155,156
 
2007  1  4 1 
157-162
 
2008  1 1 2 5 
163-171
 
2009    1 1 
172,173
 
2010  4   3 
174-180
 
2011  2 1 1 6 
181-190
 
2012  3 1 3 4 
191-200
 
2013 1 4  1 7 
201-212
 
2014     1 
213
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Figure 1.4 Overview of the application of different instrumental techniques for the analysis of eicosanoids in cell 
cultures 
 
The introduction of mass spectrometers coupled to HPLC has emerged as a potent alternative to 
overcome the limitations imposed by the use of spectrophotometric detectors (e.g. UV or DAD). The 
key to combine a MS to HPLC is the ability to remove the solvent and transfer analytes into vacuum 
as ionic species. Since the first HPLC/MS interface was reported
214
, many investigators attempted to 
improve the interface and then HPLC-MS got more and more extensive application. 
Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) are the two 
most widely used ion source in HPLC-MS. In ESI, the eluent solution passes through the 
electrospray capillary where a high voltage is applied to the tip of the capillary and as a consequence, 
the sample emerging from the tip is dispersed into an aerosol of highly charged droplets. The charged 
droplets are diminished in size by solvent evaporation. Eventually charged samples ions, free from 
solvent, are released from the droplets, some of which pass through a sampling cone into vacuum 
region and from there into the mass analyzer.  It is worth mentioning that, in this step, it is easy to 
produce multiply charged ions. Thus, sample solutions for ESI are usually buffered or have added 
acids to enhance and control of the formation ions. In APCI, analyte solutions are first desolvated in 
a heated quartz tube, and then ions are produced by interacting with a corona discharge creating ions. 
Usually, the ESI is well-suited to the analysis of the polar molecules while APCI is a better choice 
for non-polar compounds. 
A common drawback of these ion sources is that both of them involve a soft ionization process 
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where few fragments can be produced. In this case, it is easy to determine the molecular weight, but 
it cannot provide enough information about the structure of the compound. To solve this problem, a 
tandem mass spectrometry can be carried out. In this technique, ions produced in the ion source can 
be separated on the basis of their m/z ratios and the selected ion can be further fragmented by adding 
extra collisional energy. The resulting fragmentation can be useful for the identification analysis. In 
this thesis, a ESI-HPLC-tandem mass spectrometry method is applied. 
1.4.2 Extraction methods 
The main methods used for the extraction of eicosanoids from cell culture media and further 
analysis by HPLC-MS is liquid-liquid extraction (LLE) and solid phase extraction (SPE). A 
chronological overview of the application of these two particular methods for the analysis of 
eicosanoids in cell cultures by HPLC-MS is shown in Figure 1.5 and Table 1.2.  
 
Table 1.2 Application of different extraction methods prior to HPLC-MS for the analysis of eicosanoids 
Year LLE SPE 
 Number of Ref. Ref. Number of Ref. Ref. 
1998 1 
104
 1 
105
 
1999     
2000     
2001 1 
123
 1 
122
 
2002 1 
131
 2 
130,132
 
2003   1 
138
 
2004   1 
142
 
2005 1 
154
 2 
152,153
 
2006   1 
156
 
2007   1 
162
 
2008 4 
167-170
 1 
171
 
2009 1 
173
   
2010 1 
179
 2 
178,180
 
2011 1 
187
 5 
185,186,188-190
 
2012 2 
197,198
 2 
199,200
 
2013 2 
208,209
 5 
203,207,210-212
 
2014 1 
213
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Figure 1.5 shows that SPE is preferred over LLE regardless of the simplicity and short 
extraction time of the latter. The main drawback of LLE is its low recovery and poor detection limit. 
In the present thesis, LLE was used initially to determine 6-keto-PGF1α and Δ17-6-keto-PGF1α by 
HPLC-MS. The latter compound (Δ17-6-keto-PGF1α) was not detected chromatographically as 
shown in Figure 1.6. 
 
Figure 1.5 Application of different extraction methods in HPLC-MS analysis of eicosanoids. 
 
 
Figure 1.6 EICs of 6-keto-PGF1α (369351+315+289+323+307+205+220+149), Δ17-6-keto-PGF1α 
(367349+331+289+269+323+313+305+298+207+185+163), and 6-keto-PGF1α--d4 
(373355+337+319+275+167) using liquid-liquid extraction combined with HPLC-MS/MS analysis 
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SPE can be seen as one type of liquid chromatography. Compounds are separated in SPE 
cartridges according to their chemical and physical properties by using different combination of 
solvents. A procedure of SPE usually contains conditioning of the cartridges, loading sample, 
washing and collecting the fractions of interest (Figure 1.7). Nowadays, it is commonly used for 
isolating compounds or concentrating and purifying compounds in analytical laboratories. 
The majority of reported SPE methods are basically focused on limited number of eicosanoids. 
In this thesis, a new SPE method was developed to simultaneously extract LTB4, PGE3, PGE2, 
6-keto-PGF1α, Δ17-6-keto-PGF1α, RvD1 and RvD2 from human and fish cell culture medium and to 
determine quantitatively their concentrations in real samples by HPLC-MS/MS.  
 
      
Figure 1.7 Device of SPE (a) and scheme of a SPE process (b) 
1.5 Experimental design 
1.5.1 Full factorial design 
A 2-level full factorial design is the most popular design for the estimation of the significance of 
effects using one or more experimental responses. In this design, the factors are set at two levels 
(designated as +1 and -1) and all the possible combination of the factors are performed. An example 
for a 2-level three factors (2
3
) design is shown in Figure 1.8, where positive (+1) means a high 
magnitude and negative (-1) represents a low magnitude of a particular factor. The number of 
experiments (N) of a 2-level full factorial design is calculated by Eq. 1.1. 
N=2
k
                                   (1.1) 
where k is the number of studied factors. 
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After performing the experiments described in Figure 1.8, the effect of each variable can be 
calculated as Eq. 1.2. 
 R = 𝑅+1̅̅ ̅̅ ̅ − 𝑅−1̅̅ ̅̅ ̅                                                                           (1.2) 
Where 𝑅+1̅̅ ̅̅ ̅ is the average response when the variable is kept at high level and  𝑅−1̅̅ ̅̅ ̅ is the 
average response when the variable is kept at low level. A positive or negative relationship between a 
response and a variable  is denoted by the final symbol of R (+ or - correlation). 
 
Figure 1.8 2
3
- full factorial design 
 
Once the magnitude of all the effects are obtained, a model describing the behaviour of R as a 
function of the variables can be built as shown in Eq. 1.3. 
R = 𝑏0 + 𝑏1[𝑥1] + 𝑏2[𝑥2] + 𝑏12[𝑥1] × [𝑥2]                                       (1.3) 
The term b0 is the intercept, b1 and b2 are the coefficents for variable x1 and x2 respectively, b12 
the coefficient for the interaction between x1 and x2. 
Although Eq.1.3 can estimate the influence of each variable and the interaction between 
different variables, its main drawback is that curvature effects cannot be estimated. 
1.5.2 Doehlert design 
A full factorial design is a powerful tool for screening significant effects, but it cannot be used to 
determine an optimal value or region. To determine an optimum, it is necessary to implement more 
complex designs where the appropriateness of linear, interaction and quadratic terms from a 
mathematical model is evaluated by mathematical and statistical tools.  
A Doehlert design is a response surface design that allows to determine an optimum region by 
performing a minimum number of experiments. The number of experiments (N) when 2 factors (k=2) 
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are evaluated can be calculated as Eq. 1.4 and their spatial distribution is shown in Figure 1.9.  
N = 2𝑘 + 𝑘 + 1                                                                          (1.4) 
 
Figure 1.9 Distribution of experimental points for a 2-level Doehlert design 
Figure 1.9 shows six experimental points are allocated in a regular hexagon with one point in 
the center. These points are also equally distributed in a circle of radius one. This uniformity makes 
the design generate information equally in all directions. Besides, a Doehlert design can be easily 
extended to study other experimental arrangements by using previous experiments
215
. For example, 
an initial experimental region (denoted in full line) can be extended to explore neighbouring domains 
as shown in Figure 1.10. 
 
Figure 1.10 Extension of a Doehlert experimental matrix from the initial 2-level matrix 
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The final model of a Doehlert design for 2 variables is given by Eq. 1.5,  which describes the 
main effects, the interaction and the second order curvature effects of the variables.  
R = 𝑏0 + 𝑏1[𝑥1] + 𝑏2[𝑥2] + 𝑏12[𝑥1] × [𝑥2] + 𝑏11[𝑥1]
2 + 𝑏22[𝑥2]
2                        (1.5) 
Where b0 is the intercept, b1 and b2 are the coefficents for variable x1 and x2 respectively, b12 the 
coefficient for the interaction of the two variables and b11 and b22 are the second order curvature 
coefficients. 
1.6 Objectives of the thesis 
1) To develop a new SPE-HPLC-MS/MS method to analyze prostaglandins, leukotrienes, 
prostacyclyns and resolvins in cultured fish and human cells in EBM-2 medium and cL-15 
medium. 
2) To determine the optimal internal standard concentrations by means of a two-factor Doehlert 
uniform shell design in two different cell culture medium (EBM-2 and cL-15). 
3) To validate the new SPE-HPLC-MS/MS method. 
4) To apply the method to salmon head kidney, salmon liver and HUVEC exposed to different 
combinations of ω-6 and ω-3 fatty acids. 
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2. Method development and method validation 
2.1 Experimental 
2.1.1Reagents 
Prostaglandin E2 (PGE2, 99%), deuterated prostaglandin E2 (PGE2-d4, 99%), prostaglandin E3 
(PGE3, 98%), leukotriene B4 (LTB4, 97%), deuterated leukotriene B4 (LTB4-d4, 99%), 6-keto 
prostaglandin F1α (6-keto-PGF1α, 98%), deuterated 6-keto prostaglandin F1α (6-keto-PGF1α-d4, 99%), 
Δ17-6-keto-Prostaglandin F1α (Δ17-6-keto-PGF1α, 98%), resolvin D1 (RvD1, 95%), resolvin D2 
(RvD2, 95%) and deuterated resolvin D2 (RvD2-d5, 95%) were purchased from Cayman Chemical 
(Ann Arbor, MI, USA). Acetonitrile (99.8 %) and formic acid (98 %) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 2-propanol (HPLC grade, 99.9 %) from Merck (Darmstadt, 
Germany). A Millipore Milli-Q system was used to produce ultra-pure water 18 MΩ (Millipore, 
Milford, USA). 
Complete cL-15 medium was prepared by mixing Leibowitch cL-15 medium with 1% glutamax, 
1% antibiotika and 10% fetal bovine serum (FBS). Complete EBM-2 medium contained EBM
TM
-2 
basal medium supplemented with 0.1 % Heparin, 0.1 % R
3
-IGF-1, 0.1 % ascorbic acid, 0.04 % 
hydrocortisone, 0.4 % h-FGF-B, 0.1 % h-EGF, 0.1 % GA-1000 and 2% FBS. 
2.1.2 Preparation of standard solutions for determining the concentration of internal standards 
The initial concentrations of PGE2, LTB4, 6-keto-PGF1α, Δ17-6-keto-PGF1α , RvD1, RvD2, 
LTB4-d4, 6-keto-PGF1α-d4 and RvD2-d5 were 100 μg/ml, the concentration of PGE3 was 1000 μg/ml 
and PGE2-d4 was 500 μg/ml. All of them were prepared by dissolving the pure standards in ethanol. 
From the initial solutions : i) stock solution ‘A’ containing 2000 ng/ml PGE2, LTB4, 
6-keto-PGF1α; ii) stock solution ‘B’ containing 2000 ng/ml PGE3, Δ17-6-keto-PGF1α , RvD1, RvD2 
and iii) stock solution ‘C‘ containing 1000 ng/ml PGE2-d4, LTB4-d4, 6-keto-PGF1α -d4, RvD2-d5 were 
prepared in two different mediums (complete cL-15 and complete EBM-2) respectively. And then, 
these stock solutions were diluted to a series of five equally spaced solutions in the range of 0.5-200 
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ng/ml containing three different levels of internal standards, according to a Doehlert design (Figure 
2.1). Every experimental point in the Doehlert design was prepared in triplicate. 
 
Figure 2.1 Doehlert design used for the determination the optimal concentration of internal standards in 
the analytical range 0.5-200 ng/ml.  
2.1.3 Extraction procedure 
The extraction method is a modification of a previously published protocol
162
. First, an aliquot 
of 100 μL of internal standard (for cL-15 medium: PGE2-d4 2000 ng/mL, LTB4-d4 250 ng/mL, 
6-keto-PGF1α-d4 500 ng/mL, RvD2-d5 450 ng/ml; for EBM-2 medium: PGE2-d4 2000 ng/mL, 
LTB4-d4 1000 ng/mL, 6-keto-PGF1α-d4 300 ng/mL, RvD2-d5 300ng/ml) was added to 1 mL of sample. 
Then, 175 μL of ethanol and 20 μL of acetic acid were added. The mixture was vortex-mixed and 
applied to SPE columns (Agilent, ASPEC Bond Elute C18, 500 mg, 3 ml, USA) which had been 
preconditioned with 2 ml of methanol and 2 ml of water. The cartridge was washed with 4 ml of 
distilled water and 4 ml of hexane to remove peptides and salts as well as polar and nonpolar 
interfering substance. The analytes were eluted with 1 ml of hexane/ethyl acetate (1:2 v/v) collected 
into glass tubes and the solvent was evaporated under a stream of nitrogen gas. The dried sample was 
redissolved in 70 μL of acetonitrile, vortex-mixed 30 s, centrifuged at 3000 rpm (1620 g) for 3 min 
and transferred to an auto sampler vial for HPLC-MS/MS analysis. 
Method development and method validation 
17 
 
2.1.4 HPLC-MS/MS analysis 
The HPLC-MS used was an Agilent 1100 series LC/MSD trap, SL model equipped with an 
electrospray interface (ESI), a quaternary pump, degasser, autosampler, thermostatted column 
compartment and a variable-wavelength UV detector. A column C18 RP 250×4.6 mm, 5μm (Alltech, 
USA) was used and kept at 40 °C in the column compartment. Nitrogen was used as nebulizing and 
drying gas at 350 
°
C. The ESI source was operated in negative ion mode and the ion optics 
responsible for getting the ions in the ion-trap such as capillary exit, skimmer, lens and octapoles 
voltages were controlled by using the Smart View option with a resolution of 13000 m/z/s 
(FWHM/m/z = 0.6-0.7). Complete system control, data acquisition and processing were done using 
the ChemStation for LC/MSD trap software 5.3 from Agilent.  
For the analysis of prostaglandins, leukotrienes and prostacylins, the solvent system was 
acetonitrile with 0.1% formic acid (v/v）and operated in isocratic mode at 0.75 ml/min. The injection 
volume was 20 l and the analysis time 15 min.  
Table 2.1 Fragmentation patters for various eicosanoids in cL15 and EBM-2 medium 
Name of 
eicosanoids 
Parent 
ion 
m/z common to both media 
m/z unique 
to cL-15 
m/z unique to EBM-2 
PGE3 349 313, 269  331 
PGE2 351 333, 315, 271   
PGE2-d4 355 337, 319, 275   
LTB4 335 317, 275, 151, 129, 109  289, 255, 195, 273, 177, 203 
LTB4-d4 339 321, 277, 319, 293, 275, 197, 179, 153, 125   
6-keto-PGF1α 369 351, 315, 289, 307, 205, 220, 149 323 333 
Δ17-6-keto-PGF1α 367 349, 331, 289, 269, 313, 305, 207, 185, 163 323, 298,  
6-keto-PGF1α -d4 373 355, 337, 319, 275, 167   
RvD1 375 141   
RvD2 375 141   
RvD2-d5 380 362, 344, 326, 282, 146, 141   
 
For the analysis of resolvins, the mobile phase consisted of solvent A: water: acetonitrile: 
formic-acid (63:37:0.02 v/v/v) and solvent B: 2-propanol: acetonitrile (50:50 v/v). The mobile phase 
was delivered in gradient mode as follows: 100% of solvent A was held for 5 min and changed into 
60% in the following 6 min and into 10% in the subsequent 2 min. Solvent A was kept in 10% for 2 
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min and then increased to 100% in 15 min. The total analysis time was 30 min, the flow rate 0.5 
mL/min and the injection volume 25 μL.  
Different fragmentation patterns were chosen for cL-15 and EBM-2 medium and they are 
shown in Table 2.1. 
2.2 Mathematics and statistics  
2.2.1 Response Factor (RF) 
In chromatography analysis, a peak area is usually proportional to the concentration of its 
corresponding compound.  However, the ratio between peak area and concentration for different 
compounds at the same level of concentration could vary due to different chemical behavior under 
the same instrumental conditions. Besides, the ratio for the same compound may also have slight 
variation because of the changing of instrumental conditions. Thus, in order to make a quantitation 
analysis, an internal standard is always introduced and the response factor (RF) for every analyte and 
internal standard is determined as Eq. 2.1. 
RF =
[𝐴]
[𝐼𝑆]
∙
𝑆𝐼𝑆
𝑆𝐴
                                                             (2.1) 
 
Where [A] and [IS] represent the concentration of analyte and internal standard respectively, 
while SIS and SA are the chromatographic peak area of the internal standard and analyte. 
2.2.2 F-test 
F-test is a statistical parametric test commonly used to compare the lack-of-fit to pure error 
variances of a predetermined mathematical model. This statistical test was applied to check the 
regression models generated from the Doehlert design and to determine the optimal concentration of 
internal standards. The process of an F-test can be seen in Table 2.2.  
Firstly, experimental RF (RFexp) was calculated according to Eq. 2.1 and the averages of each 
triplicate were obtained. Then, a regression model like Eq. 2.2 can be built and the calculated RF 
(RFcal) were obtained from this model. 
RF = 𝑏0 + 𝑏1[𝐴] + 𝑏2[𝐼𝑆] + 𝑏12[𝐴] × [𝐼𝑆] + 𝑏11[𝐴]
2 + 𝑏22[𝐼𝑆]
2                          (2.2) 
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After that, the sum of residual error (VRE), pure error (VPE) and lack-of-fit (VLOF) were 
calculated according to Eq. 2.3—Eq. 2.5. And the F-value can be calculated by the ratio between 
VLOF and VPE.  
𝑉𝑅𝐸 =
∑(𝑅𝐹𝑒𝑥𝑝−𝑅𝐹𝑐𝑎𝑙)
2
𝑁−𝑃
                                                           (2.3) 
 
𝑉𝑃𝐸 =
∑(𝑅𝐹𝑒𝑥𝑝−𝑅𝐹̅̅ ̅̅ )
2
𝑁−𝐾
                                                             (2.4) 
 
𝑉𝐿𝑂𝐹 =
∑(𝑅𝐹𝑐𝑎𝑙−𝑅𝐹̅̅ ̅̅ )
2
𝐾−𝑃
                                                              (2.5) 
 
𝐹𝑐𝑎𝑙 =
𝑉𝐿𝑂𝐹
𝑉𝑃𝐸
                                                                      (2.6) 
N, P, K are the number of total experiments, number of regression coefficients and number of 
experimental points respectively. 
If Fcal is lower than the theoretical F-value (calculated by using Excel 2010), it means the model 
is fitted. In some instances, it is possible to remove the non-significant regression coefficients from 
Eq. 2.2 to increase the degree of freedom and obtain a simplest model (aka reduced models). In this 
thesis, all the theoretical F-values were calculated at the 95 % confidence level of F-distribution. 
 
Table 2.2 Schematic explanation of the F-test applied to determine the validity of the various regression 
models of the response factor (RF). The best models are subsequently used to determine optimal 
concentrations of internal standards 
 [A] [IS] RFexp RFcal 𝑅𝐹̅̅ ̅̅  Residual error (VRE) Pure error (VPE) Lack of fit (VLOF) 
 [A]11 [IS]11 RFexp11 RFcal11 𝑅𝐹1̅̅ ̅̅ ̅ (RFexp11- RFcal11)
2
 (RFexp11-𝑅𝐹1̅̅ ̅̅ ̅)
2
 (RFcal11-𝑅𝐹1̅̅ ̅̅ ̅)
2
 
 [A]12 [IS]12 RFexp12 RFcal12 𝑅𝐹1̅̅ ̅̅ ̅ (RFexp12- RFcal12)
2
 (RFexp12-𝑅𝐹1̅̅ ̅̅ ̅)
2
 (RFcal12-𝑅𝐹1̅̅ ̅̅ ̅)
2
 
 [A]13 [IS]13 RFexp13 RFcal13 𝑅𝐹1̅̅ ̅̅ ̅ (RFexp13- RFcal13)
2
 (RFexp13-𝑅𝐹1̅̅ ̅̅ ̅)
2
 (RFcal13-𝑅𝐹1̅̅ ̅̅ ̅)
2
 
 . 
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. 
. 
. 
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. 
. 
. 
. 
. 
. 
. 
. 
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 [A]71 [IS]71 RFexp71 RFcal71 𝑅𝐹7̅̅ ̅̅ ̅ (RFexp71- RFcal71)
2
 (RFexp71-𝑅𝐹7̅̅ ̅̅ ̅)
2
 (RFcal71-𝑅𝐹7̅̅ ̅̅ ̅)
2
 
 [A]72 [IS]72 RFexp72 RFcal72 𝑅𝐹7̅̅ ̅̅ ̅ (RFexp72- RFcal72)
2
 (RFexp72-𝑅𝐹7̅̅ ̅̅ ̅)
2
 (RFcal72-𝑅𝐹7̅̅ ̅̅ ̅)
2
 
 [A]73 [IS]73 RFexp73 RFcal73 𝑅𝐹7̅̅ ̅̅ ̅ (RFexp73- RFcal73)
2
 (RFexp73-𝑅𝐹7̅̅ ̅̅ ̅)
2
 (RFcal73-𝑅𝐹7̅̅ ̅̅ ̅)
2
 
DF.   N P K N-P N-K K-P 
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2.2.3 Statistical Software 
All of the basic calculation and F-test were carried out in Excel (Microsoft Office Excel 2010). 
2.3 Results and discussion 
 2.3.1Determination of the concentrations of internal standards 
The seven standards in Doehlert design, prepared in triplicates, were injected randomly into the 
chromatography system. Extracted ion chromatograms (EICs) were used for the quantitative 
analysis.  
2.3.1.1 Optimal concentrations of internal standards in EBM-2 medium 
The EICs and corresponding mass spectra of different analytes and internal standards in EBM-2 
medium are shown in Figure 2.2-2.5. 
 
 
Figure 2.2 EICs (a-b) and mass spectra(c-d) of leukotrienes in EBM-2 medium 
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Figure 2.3 EICs (a-c) and mass spectra (d-f) of prostaglandins in EBM-2 medium 
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Figure 2.4 EICs (a-c) and mass spectra (d-f) of prostacylins in EBM-2 medium 
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Figure 2.5 EICs (a-b) and mass spectra (c-e) of resolvins in EBM-2 medium 
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The regression models for different RFs as a function of the concentration of analytes and 
internal standards were built in Excel 2010 and F-test was used to check the fitness of the models. 
After reduction, the final models are listed in Eq. 2.7—Eq. 2.13 and the corresponding response 
surface are shown in Figure 2.6-2.9. Table 2.3 summarizes the results of F-test of the final models. 
Eq. 2.2 is valid for describing RF as a function of the concentration of PGE2 and PGE2-d4, and a 
six-parameter model is built (Eq. 2.7). It is clear from Figure 2.6a that between 100-140 ng/ml of 
PGE2-d4, the RF remains constant in the analytical range 50-200 ng/ml of PGE2.  However, a larger 
variation occurs below the above mentioned analytical concentration range. 
RF = −3.76 × 10−1 + 1.21 × 10−2[𝑃𝐺𝐸2] + 8.21 × 10
−3[𝑃𝐺𝐸2 − 𝑑4] 
+1.72 × 10−5[𝑃𝐺𝐸2] × [𝑃𝐺𝐸2 − 𝑑4] − 6.19 × 10
−5[𝑃𝐺𝐸2]
2 − 2.98 × 10−5[𝑃𝐺𝐸2 − 𝑑4]
2              (2.7) 
The calculated F-values for the various constructed RF regression models as a function of PGE3 
and PGE2-d4 are higher than the theoretical F-values (95% confidence), thus, the modeling of PGE3 
was carried out by using the inverse of RF (1/RF). The fitted model (Eq. 2.8) is shown in Figure 
2.6b. The RF remains constant in the whole studied PGE3 range when the concentration of PGE2-d4 
is in the region of 0.5-50 ng/ml and 180-200 ng/ml. The relative standard deviation of RF in region 
of 0.5-50 ng/ml (35%) is higher than that in 180-200 ng/ml (11%).  
1
RF
= 4.14 − 1.12 × 10−2[𝑃𝐺𝐸3] − 3.64 × 10
−2[𝑃𝐺𝐸2 − 𝑑4] + 5.83 × 10
−5[𝑃𝐺𝐸3] × [𝑃𝐺𝐸2 − 𝑑4] 
+8.96 × 10−5[𝑃𝐺𝐸2 − 𝑑4]
2                                                                                                                        (2.8) 
The concentration of 182 ng/ml of PGE2-d4 is selected as the optimal concentration to analyze 
quantitatively PGE2 and PGE3 in EBM-2 medium, based on the experimental evidence summarized 
in Figure 2.6. 
 
Figure 2.6 Behavior of RFs as a function of (a) PGE2 and PGE2-d4; (b) PGE3 and PGE2-d4 in EBM-2 medium, 
values in the figures represent the mean ± standard deviation of RFs. 
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A four-parameter polynomial function was built between RF and concentrations of LTB4 and 
LTB4-d4 (Eq. 2.9) and it exhibited a non-significant lack-of fit to pure error variance ratio of 2.343 
(Table 2.3).  The graph (Figure 2.7) displays three major regions, in which the major variation of 
RF is along LTB4–d4 axis. RF keeps constant when LTB4-d4 is between 75-125 ng/ml. Thus, 91 
ng/ml is chosen as the optimal concentration of LTB4-d4 for the analysis of LTB4 in EBM-2 medium. 
RF = −4.02 × 10−1 + 8.27 × 10−3[𝐿𝑇𝐵4] + 1.90 × 10
−2[𝐿𝑇𝐵4 − 𝑑4] 
−9.70 × 10−5[𝐿𝑇𝐵4] × [𝐿𝑇𝐵4 − 𝑑4]                                                                                                       (2.9) 
 
Figure 2.7 Behavior of RF as a function of LTB4 and LTB4-d4 in EBM-2 medium, values in the figures 
represent the mean ± standard deviation of RFs 
 
The modeling of 6-keto-PGF1α was also carried out by using 1/RF. The model (Eq. 2.10) was 
only a function of the concentration of 6-keto-PGF1α and independent of the concentration of internal 
standard (Eq. 2.10). There are three different RF values in three different 6-keto-PGF1α concentration 
regions, namely 0.5-45 ng/ml (0.65±0.01), 45-148 ng/ml (0.69±0.02) and 148-200 ng/ml (0.74±
0.01) regardless of the concentration of the internal standard.  
1
𝑅𝐹
= 1.56 − 1.19 × 10−3[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼]                                   (2.10) 
For Δ17-6-keto-PGF1α, RF was a linear function of the concentration of Δ17-6-keto-PGF1α and 
6-keto-PGF1α-d4 (Eq. 2.11). There are two main concentration regions (Figure 2.8) where RF 
remains constant between 0.5-50 ng/ml (green region in Figure 2.8b) and 100-150 ng/ml (purple 
region in Figure 2.8b) of 6-keto-PGF1α-d4 in the analytical range of 0.5-200 ng/ml of 
Δ17-6-keto-PGF1α. In general, it is advisable to use low concentrations of internal standard due to the 
high cost of the eicosanoid standards used in the present investigation (for example, 1 mg of 
Δ17-6-keto-PGF1α costs 1200 Euros). Based on this particular consideration, a concentration of 27 
ng/ml of internal standard was selected as the optimal level for the determination of 6-keto-PGF1α 
and Δ17-6-keto-PGF1α in EBM-2 medium.   
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RF = 1.33 − 1.36 × 10−3[∆17 − 6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼] + 4.09 × 10
−3[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼 − 𝑑4]      (2.11) 
 
Figure 2.8 Behavior of RF as a function of (a) 6-keto-PGF1α and 6-keto-PGF1α-d4; (b) Δ17-6-keto-PGF1α and 
6-keto-PGF1α-d4 in EBM-2 medium, values in the figures represent the mean ± standard deviation of RFs 
 
For RvD1, the RF was only affected by the concentration of RvD2-d5 (Eq. 2.12) and was 
independent of the concentration of RvD1 in the range 0.5-200 ng/ml as demonstrated in Figure 2.9a 
and Eq. 2.12.  
RF = 6.59 × 10−1 − 8.45 × 10−4[𝑅𝑣𝐷2 − 𝑑5]               (2.12) 
For RvD2, a three-parameter function was built (Eq. 2.13). The graph displayed in Figure 2.9b 
shows that RF is constant between 50-200 ng/ml of RvD2 when RvD2-d5 is varied between 0.5-50 
ng/ml. This particular region is regarded as optimal for the analysis of real samples.  Based on the 
previous results (Figure 2.9 and Eq. 2.12 -2.13), 27 ng/ml of RvD2-d5 is considered as the optimal 
level for the determination of RvD1 and RvD2 in EBM-2 medium.  
RF = 5.01 × 10−1 + 1.70 × 10−3[𝑅𝑣𝐷2] + 1.09 × 10
−3[𝑅𝑣𝐷2 − 𝑑5]                  (2.13) 
 
 
Figure 2.9 Behavior of RF as a function of (a) RvD1 and RvD2-d5; (b) RvD2 and RvD2-d5 in EBM-2 medium, 
values in the figures represent the mean ± standard deviation of RFs 
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Table 2.3 Statistical validation results of the RF models for selecting optimal levels of internal standards 
associated to the analysis of different eicosanoids generated by human cells in EBM-2 medium 
 PGE3 PGE2 LTB4 6-keto-PGF1α Δ-17-6-keto-PGF1α RvD1 RvD2 
Residual variance 1.566 (14) 0.233(13) 28.190(17) 0.321(16) 2.880(15) 0.110(11) 0.316(10) 
Pure error variance 0.986(12) 0.213(12) 18.767(14) 0.204(12) 2.097(12) 0.051(7) 0.192(7) 
Lack-of-fit 
variance 
0.580(2) 0.020(1) 9.423(3) 0.117(4) 0.784(3) 0.059(4) 0.125(3) 
Festimated 3.528 1.109 2.343 1.720 1.495 2.017 1.518 
Ftheoretical 3.885 4.747 3.344 3.259 3.490 4.120 4.347 
 
2.3.1.2 Optimal concentrations of internal standards in cL-15 medium 
The procedure to select the optimal levels of internal standards in cL-15 medium was similar to 
the procedure described in the previous section. The EICs and corresponding mass spectra of 
different eicosanoids are shown in Figure 2.10-2.13. Some of the characteristic peaks for LTB4 
(specifically m/z 192, 255, 289 in Figure 2.10c) were observed in cL-15 blank medium (Figure 2.14) 
and consequently they were excluded for quantification purposes.  
 
 
Figure 2.10 EICs (a-b) and mass spectra (c-d) of leukotrienes in cL-15 medium 
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Figure 2.11 EICs (a-c) and mass spectra (d-f) of prostaglandins in cL-15 medium 
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Figure 2.12 EICs (a-c) and mass spectra (d-f) of prostacylins in cL-15 medium 
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Figure 2.13 EICs (a-b) and mass spectra (c-e) of resolvins in cL-15 medium. 
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Figure 2.14 EICs of LTB4 in blank medium when the fragmentation is:  
 (a) 335→317+275+289+273+255+192+203+177+151+129+109; (b) 335→317+275+151+129+109 in 
cL-15 medium 
 
The validated models describing the behavior of RF as a function of different internal standards 
and analytes are described in Eqs 2.14 - 2.20. 
The optimal concentration of PGE2- d4 was selected by simultaneously considering the behavior 
of RF for PGE2 and PGE3 (Figure 2.15). The concentration plot of PGE2-d4 versus PGE2 shows 
three well differentiated regions (indicated in blue, brown and red in Figure 2.15a) along the   
PGE2-d4 axis. In these particular regions, RF remains constant over the entire PGE2 range. It has 
been mentioned that low concentration levels are preferred due to the high cost of the pure 
eicosanoid standards. However, based on Figure 2.15a, it is advisable to use high concentrations of 
PGE2-d4 (between 175-200 ng/ml) due to the high coefficient of variation (CV= 100×0.13/0.15=87%) 
observed in the concentration range of 0.5-130 ng/ml of PGE2-d4. Similar observations to those 
described above were derived from Figure 2.15b for PGE3. The high coefficient of variation (approx. 
56%) in the concentration range 0.5-130 ng/ml of PGE2-d4 precluded the use of this particular range. 
Consequently, 182 ng/ml of PGE2-d4 is chosen for further analysis of PGE2 and PGE3 in cL-15 
medium. 
RF = 2.48 × 10−1 − 1.77 × 10−4[𝑃𝐺𝐸2] − 7.47 × 10
−3[𝑃𝐺𝐸2 − 𝑑4] + 6.94 × 10
−5[𝑃𝐺𝐸2 − 𝑑4]
2    (2.14) 
 
RF = 1.27 × 101 − 2.22 × 10−1[𝑃𝐺𝐸3] − 6.03 × 10
−2[𝑃𝐺𝐸2 − 𝑑4] + 1.13 × 10
−3[𝑃𝐺𝐸3]
2 
+8.59 × 10−4[𝑃𝐺𝐸2 − 𝑑4]
2                                                                                                             (2.15) 
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Figure 2.15 Behavior of RF as a function of (a) PGE2 and PGE2-d4; (b) PGE3 and PGE2-d4 in cL-15 medium, 
values in the figures represent the mean ± standard deviation of RFs 
 
Three concentrations of LTB4-d4 (27, 70 and 190 ng/ml) were observed where RF values remain 
almost constant in the whole analytical range (Figure 2.16). Based on eicosanoid price 
considerations, a concentration of 27 ng/ml of LTB4-d4 was selected for the analysis of LTB4 in cL-15 
medium. 
RF = 1.53 + 2.82 × 10−3[𝐿𝑇𝐵4] − 2.03 × 10
−2[𝐿𝑇𝐵4 − 𝑑4] + 7.84 × 10
−5[𝐿𝑇𝐵4 − 𝑑4]
2      (2.16) 
 
Figure 2.16 Behavior of RF as a function of LTB4 and LTB4-d4 in cL-15 medium, values in the figures 
represent the mean ± standard deviation of RFs 
 
The behavior of RF for 6-keto-PGF1α (Figure 2.17a) was similar to that described in Figure 
2.16. An optimal concentration region between 35-50 ng/ml of 6-keto-PGF1α-d4 over the entire 
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6-keto-PGF1α range was observed (Figure 2.17a). Considering that the behavior of RF for 
Δ17-6-keto-PGF1α was independent of 6-keto-PGF1α-d4 (Figure 2.17b), it was decided that 45 ng/ml 
of internal standard represents the optimal amount of 6-keto-PGF1α-d4 for the analysis of 
6-keto-PGF1α and Δ17-6-keto-PGF1α produced by fish cells in cL-15 medium. 
RF = 9.98 × 10−1 + 8.04 × 10−4[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼] − 4.41 × 10
−3[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼 − 𝑑4] 
+1.49 × 10−5[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼 − 𝑑4]
2                                                                                                (2.17) 
 
RF = 3.16 − 8.07 × 10−3[∆17 − 6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼] + 4.00 × 10
−3[6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼 − 𝑑4] 
−3.81 × 10−5[∆17 − 6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼][6 − 𝑘𝑒𝑡𝑜 − 𝑃𝐺𝐹1𝛼 − 𝑑4]                                             (2.18) 
 
Figure 2.17 Behavior of RF as a function of (a) 6-keto-PGF1α and 6-keto-PGF1α-d4; (b) Δ17-6-keto-PGF1α and 
6-keto-PGF1α-d4 in cL-15 medium, values in the figures represent the mean ± standard deviation of RFs 
 
Similar regression models were derived for RvD1 and RvD2 where RF values were expressed as 
functions of RvD1 or RvD2, their common internal standard (RvD2-d5) and the interaction between 
them (Eq. 2.19 and Eq. 2.20). The second-order terms were not significant in both cases. For RvD1, 
the RF was constant at concentration levels below 20 ng/ml of RvD2-d5 (Figure 2.18a). However, at 
this particular level the chromatographic peak exhibited a noisy baseline. For RvD2, the RF was 
constant (1.88±0.14) in the range of 40-110 ng/ml of RvD2-d5 (Figure 2.18b). It was decided that 
41 ng/ml of RvD2-d5 represent an optimal concentration level for the analysis of RvD1 and RvD2 
generated by fish cells in cL-15 medium. 
RF = 1.03 + 6.57 × 10−5[𝑅𝑣𝐷1] + 2.89 × 10
−3[𝑅𝑣𝐷2 − 𝑑5] − 2.47 × 10
−5[𝑅𝑣𝐷1][𝑅𝑣𝐷2 − 𝑑5]          (2.19) 
 
RF = 1.29 + 4.70 × 10−3[𝑅𝑣𝐷2] + 7.27 × 10
−3[𝑅𝑣𝐷2 − 𝑑5] − 5.27 × 10
−5[𝑅𝑣𝐷2][𝑅𝑣𝐷2 − 𝑑5]          (2.20) 
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Figure 2.18 Behavior of RF as a function of (a) RvD1 and RvD2-d5; (b) RvD2 and RvD2-d5 in cL-15 medium, 
values in the figures represent the mean ± standard deviation of RFs. 
 
Table 2.4 Statistical validation results of the RF models for selecting optimal levels of internal standards associated to the 
analysis of different eicosanoids generated by fish cells in cL-15 medium 
 PGE3 PGE2 LTB4 6-keto-PGF1α Δ-17-6-keto-PGF1α RvD1 RvD2 
Residual variance 198.461(16) 0.389(17) 2.715(17) 0.600(14) 10.636(14) 0.696(14) 1.376(14) 
Pure error 
variance 
197.085(14) 0.324(14) 2.157(14) 0.587(12) 10.019(12) 0.634(12) 1.056(12) 
Lack-of-fit 
variance 
1.375(2) 0.066(3) 0.558(3) 0.013(2) 0.617(2) 0.062(2) 0.320(2) 
Festimated 0.049 0.945 1.206 0.137 0.369 0.591 1.819 
Ftheoretical 3.739 3.344 3.344 3.885 3.885 3.885 3.885 
2.3.2 Method validation 
Method validation is a process that defines the analytical characteristics of a method. Usually, 
once a new method is developed, its validation is necessary to confirm its precision and reliability.  
After selecting the optimal internal standard concentrations, the developed SPE-HPLC-MS/MS 
method described in Section 2.1 was submitted to analytical validation. The validation parameters 
considered in the present study were: selectivity, LOD, LOQ, linearity, analytical range, precision 
and recovery.  
2.3.2.1 Selectivity 
According to IUPAC, the term selectivity is defined as “the extent to which a method can 
determine a particular analyte in a complex mixture without interference from other components in 
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the mixture” 216.  The definition in question implies that the signal should be only due to the 
occurrence of analyte. This is considered the most important parameter in a method validation.  
One advantage of chromatography is its separation ability. Compounds are separated and eluted 
in different retention times which can guarantee the selectivity. However, many analytes from the 
same category have similar retention times such as PGE2 and PGE3. In this case, to guarantee the 
selectivity, mass spectra are needed.  
The developed SPE-HPLC-MS/MS method was highly selective as showed in the different EICs 
for leukotrienes (Figure 2.2a-Figure 2.2b and Figure 2.10a-Figure 2.10b), prostaglandins (Figure 
2.3a-Figure 2.3c and Figure 2.11a-Figure 2.11c)), prostacyclyns (Figure 2.4a-Figure 2.4c and Figure 
2.12a-Figure 2.12c)) and resolvins (Figure 2.5a-Figure 2.5b and Figure 2.13a-Figure 2.13b)) in both 
media, EBM-2 medium and cL-15 medium. 
2.3.2.2 Limit of detection (LOD) and limit of quantification (LOQ) 
LOD is the smallest concentration of analyte that can be detected with statistically significant 
certainty while the LOQ is the smallest concentration of analyte that can be quantified with an 
acceptable accuracy and precision. They can be determined by a) visual inspection of a recorded 
signal; b) the slope of a calibration curve; and c) the signal to noise ratio of a blank sample 
216
.  
In the present thesis, the last approach (c) was used to determine the LOD and LOQ as follows: 
blank samples are injected in pentaplicate (for each type of medium), the corresponding EICs of the 
studied eicosanoids are obtained, their areas at specific retention times are monitored and the 
standard deviations for each type of blank medium (σblank) calculated. The LOD and LOQ are defined 
by the concentrations of spiked medium solutions that are able to produce analytical signals 
equivalent to 3×σblank and 6×σblank . The LOD and LOQ values determined experimentally are shown 
in Table 2.5 and Table 2.6.  
2.3.2.3 Linearity and analytical range 
Linearity is the ability of an analytical method to provide an analytical response proportional to 
the concentration or the amount of analyte within a specified range. Whereas, the range of an 
analytical method is defined as the interval between LOQ and upper concentration (amounts) of 
analyte in the sample for which it has been demonstrated that the analytical procedure has an 
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acceptable level of precision, accuracy and linearity. Mathematically, linearity is expressed as Eq. 
2.21: 
                    𝑦 =  𝑎 (𝑥)  +  𝑏                                     (2.21)                                                  
where y, in the present case, is the analyte/internal standard signal ratio, x is the analytical 
concentration and a and b are the slope an intercept of the calibration function respectively.  
2.3.2.4 Precision 
Precision is the closeness of agreement between measured values obtained by replicate 
measurements on the same or similar objects under specified conditions. Repeatability, intermediate 
precision and reproducibility are three terms associated with precision.  
Repeatability is the precision of results obtained in the same measurement conditions (analyst, 
laboratory, instrument, etc.) over a short period of time.  
Intermediate precision is the precision of results obtained in a given laboratory over an extended 
period of time. 
Reproducibility is the precision of results obtained by changing one or more measurement 
conditions over a short or an extended period of time. 
In this thesis, the relative standard deviation of triplicate spiked medium solutions at low, 
medium and high concentration levels  of specific eicosanoids (50, 100 and 200 ng/ml respectively) 
are used to determine the precision of the method. The results (Tables 2.5-2.6) revealed acceptable 
levels of precision for EBM-2 medium (0.2-27.3%) and cL-15 medium (3.5-30.7%). The precision 
results fulfilled the requirements for biological samples (≤30%)217. 
2.3.2.5 Recovery 
Recovery is a parameter to measure accuracy which is defined as the closeness of agreement 
between a measured value and true value. The ratio between the measured to nominal concentration 
is referred as recovery and it is generally expressed in percentage units (%).  
In the present thesis, the recovery studies were carried out by adding known amounts of the 
various analytes into blank media (EBM-2 and cL-15) to make concentrations of 50, 100 and 200 
ng/ml of the various eicosanoids. Every level of concentration was prepared in triplicate. The 
recoveries of different analytes varied from 57.1% to 127.2 % for EBM-2 medium and from 63.9% 
to 128.4% for cL-15 medium. A statistical analysis for the wide recovery range observed for PGE3 
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and LTB4 in EBM-2 medium was performed by obtaining the z values and computing the normal 
distribution function. The results (Appendix I) allow to conclude that in those ranges (for PGE3 and 
LTB4), the concentrations will lie between ±2σ of the normal curve and consequently they are 
considered acceptable ranges. It is important to mention that these results were discussed with an 
expert in biological cell culture experiments who considered that these recovery ranges were very 
strict when compared to the wider levels of variation expected in cell experiments. 
Table 2.5 Method validation parameters in EBM-2 medium 
 LOD (ng/ml) LOQ (ng/ml) Recovery (%) Range (ng/ml) Precision (%) 
PGE2 0.1 0.1 81.0-120.9 0.1-200 1.4-16.3 
PGE3 0.1 0.1 60.9-120.9 0.1-200 2.0-13.6 
LTB4 0.1 0.1 57.1-118.2 0.1-200 11.2-20.7 
6-keto-PGF1α 0.1 0.6 91.4-108.8 0.6-200 6.2-14.4 
Δ17-6-keto-PGF1α 0.1 0.6 88.9-127.2 0.6-200 8.4-24.1 
RvD1 0.1 0.1 87.6-124.5 0.1-200 0.2-22.2 
RvD2 0.1 0.1 83.2-109.6 0.1-200 1.4-5.7 
 
Table 2.6 Method validation parameters for cL-15 medium 
 LOD (ng/ml) LOQ (ng/ml) Recovery (%) Range (ng/ml) Precision (%) 
PGE2 0.1 0.1 63.9-128.4 0.1-200 4.5-30.7 
PGE3 0.6 8.0 93.6-124.5 8-200 5.4-19.5 
LTB4 0.1 0.3 67.0-115.1 0.3-200 10.4-28.0 
6-keto-PGF1α 0.1 0.1 96.8-115.2 0.1-200 3.5-18.4 
Δ17-6-keto-PGF1α 2.0 8.0 88.6-125.7 8-200 9.6-21.3 
RvD1 0.6 1.0 97.7-118.2 1-200 10.5-28.1 
RvD2 0.3 0.6 91.4-112.0 0.6-200 9.1-26.2 
2.4 Conclusions 
In this chapter, a new SPE-HPLC-MS/MS method was developed to simultaneously analyze 
seven eicosanoids (PGE2, PGE3, LTB4, 6-keto-PGF1α, Δ17-6-keto-PGF1α, RvD1 and RvD2) in cL-15 
medium and EBM-2 medium. The optimal concentrations of internal standards were selected by an 
experimental design and different validation parameters are also defined. The method has proved to 
be selective, precise, accurate and suitable for the analysis of eicosanoids generated by human cells 
in EBM-2 medium and fish cells in cL-15 medium. 
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3. Application of the method to Salmon liver cells 
3.1 Experimental 
3.1.1 Reagents 
Complete cL-15 medium was prepared by mixing Leibowitch L-15 medium with 1% glutamax, 1% 
antibiotika and 10% FBS. 
1 M CaCl2 and perfusion buffer containing 1.4 M NaCl, 0.067M KCl and 0.09M Hepes Sodium Salt at 
pH 7.4 were prepared and used as stock solutions.  
Perfusion buffer containing EDTA was prepared by adding 1.11 g EDTA disodium salt to 20 ml of 
perfusion buffer and diluted to 200 mL using ultra-pure water; pH was finally adjusted to 7.4.  
Perfusion buffer containing collagenase was prepared by first diluting 10 ml of perfusion buffer to 100 
mL and adjusting pH=7.4. Then, 100 μL 1M CaCl2 and 100 mg collagenase were added. Both of buffers 
containing EDTA and collagenase should be freshly prepared. 
3.1.2 Isolation of the cells 
The fish were anaesthetized by metacaine (MS222, 0.5 gram/10 L) and the livers were perfused with a 
perfusion buffer containing EDTA at a flow of 4 ml/min until free of blood. Thereafter, the livers were 
digested with collagenase (collagenase dissolved in stock perfusion buffer as describe before). The isolated 
cells were harvested in 10 ml 10% phosphate-buffered saline buffer (PBS buffer: 0.002M KH2PO4, 0.02M 
Na2HPO4, 0.03M KCl and 0.14M NaCl, pH 7.4), filtrated through a 100 µm mesh cell strainer and washed 
twice in the PBS buffer, re-suspended in cL-15 medium before the viability of the isolated cells was assessed. 
All centrifugations were done by 50 g for 5 min. The viability of the liver cells was above 90% (range: 90.8 
to 94.4%). The isolations of cells were done with sterile equipment and buffers. 
3.1.3 Cell culture 
The culture plate was first conditioned by adding 1% Laminin (500 μL Laminin in 50 mL PBS) 1920 
μL/well and kept overnight. Once the cells were obtained, these solutions were removed and 1.67×106 liver 
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cells were added to each well. According to the 2
4
- full factorial design (Table 3.1), different combinations 
of fatty acids were added. At each experimental point, triplicate was done. 
When the signal is positive (+), 0.5 mL medium containing the corresponding fatty acid with a 
concentration of 46 μM was added. Different fatty acids were first attached to FBS and then complete cL-15 
medium was prepared using this FBS instead of normal one. When the signal is negative (-), 0.5 mL normal 
complete cL-15 medium was added. At 16
th
 experimental point, besides 2 ml normal complete medium, 25 
μL of ethanol were also added.   
After incubating 24 h at 9 °C in an incubator device (Sanyo Electric CO., Ltd., Osaka, Japan), the 
medium was collected carefully without disturbing the cells attached to the bottom of the plate and stored at 
-80 °C until the analysis by HPLC-MS/MS 
 
Table 3.1 2
4
-
 
full factorial design 
 LA AA EPA DHA 
1 + + + + 
2 + + + - 
3 + + - + 
4 + + - - 
5 + - + + 
6 + - + - 
7 + - - + 
8 + - - - 
9 - + + + 
10 - + + - 
11 - + - + 
12 - + - - 
13 - - + + 
14 - - + - 
15 - - - + 
16 - - - - 
  
 
3.2 Statistical analysis 
3.2.1 Multifactor ANOVA 
Usually, analysis of variance (ANOVA) is used to detect significant factors. When there is only one 
factor influencing the experimental response, one-way ANOVA can be used. However, when several 
variables are affecting the experimental response, multifactor ANOVA is applied. In this section, the 
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multifactor ANOVA theory is explained by using as an example a 2
4
- full factorial design (Table 3.2). 
 
Table 3.2 Example of a 2
4
 -factorial design used for the explanation of multifactor ANOVA 
NO. Code Responses Mean Response Mean in each group 
1 + X1-1 X1-2 X1-3 X1  
. 
. 
. 
      
X+ 
8 + X8-1 X8-2 X8-3 X8  
9 - X9-1 X9-2 X9-3 X9  
. 
. 
. 
 . 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
 
X_ 
16 - X16-1 X16-2 X16-3 X16  
     Global mean X 
 
In a 2
4
- factorial design, 16 experimental points are set and measured preferably in triplicate. From the 
measured responses, the following values are calculated: mean response of each triplicate (Xi ), mean 
response when the corresponding factor is negative (X_  ), mean response when the factor is positive (X+ ) 
and mean response of all the experiments (X ).  
Then, mean square of effect and mean square of error can be calculated according to Eq. 3.1 and Eq. 
3.2, respectively. F-value is defined as the ratio between MSeffect  and MSerror (Eq. 3.3).  
 
𝑀𝑆𝑒𝑓𝑓𝑒𝑐𝑡 =
[∑(?̅?−𝑋+̅̅ ̅̅ )
2
+∑(?̅?−𝑋−̅̅ ̅̅ )
2
](N×K)
2−1
                               (3.1) 
 
𝑀𝑆𝑒𝑟𝑟𝑜𝑟 =
∑(𝑥?̅?−𝑋𝑖−𝑗)
2
P−R
                                                    (3.2)  
 
F =
𝑀𝑆𝑒𝑓𝑓𝑒𝑐𝑡
𝑀𝑆𝑒𝑟𝑟𝑜𝑟
                                                                 (3.3) 
 
Where N is the number of experimental points in each group, K is the number of the replicates, P is the 
total number of experiments, and R is the total number of experimental points. 
Thereafter, the corresponding confidence level related to F-value can be calculated in Excel 2010. 
Usually, if the confidence level is higher than 95% (p-value lower than 0.05), the factor is considered 
statistically significant. 
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3.2.2 Fisher’s Least Significant Difference (LSD) test 
LSD is a test that can compare the mean of two groups. In this test, the square root of the mean square 
error from ANOVA is considered to be a pooled standard deviation. Considering the sample size of the two 
groups being compared, a standard error of difference between those two means is calculated. LSD is 
defined as the product of this standard error multiplied by a t-value in a confidence level (Eq. 3.4). 
 
LSD = 𝑡𝑣,𝛼√𝑀𝑆𝑒𝑟𝑟𝑜𝑟
2
𝑁
                                                      (3.4) 
 
Where N is the number of observations in each group, v is the degrees of freedom and it is equal to 
2N-2, α is the significance level which is often used as 0.05. MSerror is the mean square of error, and it is 
calculated as the way in one-way ANOVA like Eq. 3.5. 
 
𝑀𝑆𝑒𝑟𝑟𝑜𝑟 =
(𝑋+̅̅ ̅̅ −𝑋𝑖𝑗)
2
+(𝑋−̅̅ ̅̅ −𝑋𝑖𝑗)
2
2𝑁−2
                         (3.5) 
 
The symbols in Eq. 3.5 have the same meaning as defined in section 3.2.1.  
3.2.3 Statistical software 
Statgraphics Centurion XV version was used for computing numerically and graphically the 
significance of the factors by means of the multifactor analysis of variance (ANOVA) and Fisher’s least 
significance options respectively. 
3.3 Results and discussion 
The developed and validated SPE-HPLC-MS/MS was successfully used for the simultaneous 
determination of prostaglandins (PGE1, PGE2), prostacyclins (6-keto-PGF1α, Δ17-6-keto-PGF1α), leukotriene 
(LTB4) and resolvins (RvD1, RvD2) generated by salmon liver cells in cL-15 medium. The production of 
prostaglandins, prostacyclins and leukotriene were effectively confirmed by the new method (Table 3.3). 
Unfortunately, the resolvins were not detected in the analyzed samples. 
 Some reports have established similar metabolic pathways (dotted circle line in Figure 1.2) for the 
isobaric resolvins RvD1, RvD2 (analyzed in this work) and RvD3, RvD4 (MW= 376).  The expected base 
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peak generated by RvD1 and RvD2 (m/z 375141) and RvD3 and RvD4 (m/z 375147)
218
 were extracted 
from the chromatograms of analyzed medium. Surprisingly, the results did not show the presence of the 
former resolvins (Figure. 3.1a). However, a significant peak for the latter resolvins (Figure 3.1b)   with 
intensity similar to its internal standard was observed. These unexpected results indicated that the major 
metabolites of DHA in salmon liver cells are RvD3 and RvD4, and not RvD1 and RvD2 (as initially assumed 
in the present thesis). 
 
Figure 3.1 EICs of the a) resolvins analyzed in this work (RvD1 and RvD2 at m/z 375141) and b) resolvins not 
analyzed in this work (RvD3 and RvD4 at m/z 375147) with their corresponding internal standard (RvD2-d5 at m/z 
380141) generated by salmon liver cells in cL-15 medium. 
 
The concentrations of other eicosanoids (PGE2, PGE3, LTB4, 6-keto-PGF1α and Δ17-6-keto-PGF1α) were 
determined by using their corresponding RF values and the results are shown in Table 3.3.  
A multifactor ANOVA was applied to study  the impact  of different fatty acids on the production of 
eicosanoids by salmon liver cells and the results of this analysis are shown in Table 3.4. The graphical 
representations of the mean concentrations of the generated eicosanoids with their corresponding 95% least 
significant intervals are shown in Figure 3.2-1 and Figure 3.2-2. 
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Table 3.3 Concentrations in ng/ml of various eicosanoids released in cL-15 medium by salmon liver cells after 
exposure to different PUFAs.  
  LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA+AA+EPA+DHA 
1.1 0.390 3.175 2.786 8.669 6.581 
1.2 0.646 6.011 1.129 30.827 8.170 
1.3 0.559 4.437 2.537 18.486 4.114 
LA+AA+EPA 
2.1 0.882 4.645 2.264 4.525 5.891 
2.2 0.932 4.610 1.115 42.721 5.998 
2.3 0.431 4.798 1.635 5.592 3.637 
LA+AA+DHA 
3.1 0.675 3.493 2.304 8.819 5.163 
3.2 1.217 2.635 0.930 4.093 4.339 
3.3 1.121 3.465 2.304 12.723 3.967 
LA+AA 
4.1 0.351 2.074 3.181 9.808 5.049 
4.2 0.589 1.105 1.115 3.206 5.803 
4.3 0.514 3.391 1.504 15.985 7.247 
LA+EPA+DHA 
5.1 0.832 0.814 0.437 8.880 0.866 
5.2 1.031 1.108 0.368 2.832 0.613 
5.3 0.684 0.354 0.381 13.408 1.115 
LA+EPA 
6.1 0.632 0.208 0.340 3.489 1.494 
6.2 0.596 0.186 0.067 4.252 0.730 
6.3 0.663 0.345 0.257 5.837 0.329 
LA+DHA 
7.1 0.191 0.326 0.642 4.427 2.733 
7.2 0.441 0.864 0.315 7.315 0.963 
7.3 0.725 0.400 0.277 10.474 0.251 
LA 
8.2 0.272 0.226 0.392 6.313 1.033 
8.2 0.351 0.131 0.245 5.576 0.658 
8.3 0.322 0.586 0.268 4.142 0.810 
AA+EPA+DHA 
9.1 0.934 4.793 3.624 6.916 7.123 
9.2 0.895 1.225 1.570 3.166 4.813 
9.3 0.954 4.418 2.279 7.228 7.517 
AA+EPA 
10.1 0.577 3.173 3.377 13.128 10.610 
10.2 0.545 4.112 2.131 11.950 7.100 
10.3 0.687 7.032 2.738 10.290 8.734 
AA+DHA 
11.1 0.738 3.463 2.945 13.109 6.782 
11.2 1.011 3.015 1.208 10.120 7.248 
11.3 0.958 6.634 1.719 7.519 6.296 
AA 
12.1 0.379 4.149 2.509 8.693 6.426 
12.2 0.503 2.191 1.890 3.337 7.110 
12.3 0.697 5.555 2.199 5.517 8.889 
EPA+DHA 
13.1 0.820 0.785 0.514 2.671 0.435 
13.2 0.890 0.831 0.601 8.731 1.628 
13.3 0.890 0.389 0.309 6.987 1.623 
EPA 
14.1 1.017 1.296 1.077 9.827 2.791 
14.2 0.687 0.979 0.759 5.039 1.639 
14.3 0.955 0.667 1.001 5.054 3.333 
DHA 
15.1 0.747 1.022 0.402 8.792 3.404 
15.2 0.361 0.383 0.181 4.154 1.410 
15.3 0.877 0.340 0.539 4.395 3.933 
with ETOH 
16.1 0.145 0.194 0.573 3.082 0.706 
16.2 0.571 0.175 0.267 4.823 0.654 
16.3 0.654 0.260 0.558 5.906 1.732 
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Table 3.4 Multifactor ANOVA results with the significant effects (P- values) for the impact of PUFAs on the 
production of various eicosanoids by salmon liver cells. 
 LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA 0.0610↓ 0.3137↓ 0.0529↓ 0.1376↑ 0.0001↓* 
AA 0.1551↑ 0.0000↑* 0.0000↑* 0.0161↑* 0.0000↑* 
EPA 0.0059↑* 0.0659↑ 0.2438↑ 0.1588↑ 0.5854↑ 
DHA 0.0008↑* 0.7625↑ 0.7779↓ 0.7269↑ 0.3530↓ 
LA*AA 0.3083↑ 0.5846↓ 0.5286↓ 0.2366↑ 0.1662↓ 
LA*EPA 0.5812↓ 0.2071↑ 0.2142↓ 0.3471↑ 0.8744↓ 
LA*DHA 0.5923↓ 0.3412↑ 0.2089↑ 0.6391↑ 0.3281↑ 
AA*EPA 0.0015↓* 0.2830↑ 0.6393↑ 0.2707↑ 0.3313↑ 
AA*DHA 0.2784↑ 0.7481↓ 0.9000↑ 0.6327↓ 0.0928↓ 
EPA*DHA 0.0338↓* 0.2053↓ 0.8630↑ 0.6379↓ 0.3067↓ 
LA*AA*EPA 0.3612↓ 0.0745↑ 0.7902↓ 0.2246↑ 0.9401↑ 
LA*AA*DHA 0.1846↓ 0.6681↑ 0.9741↑ 0.8487↓ 0.3168↑ 
LA*EPA*DHA 0.3740↓ 0.5459↑ 0.4550↑ 0.2962↑ 0.0102↑* 
AA*EPA*DHA 0.1344↓ 0.3329↓ 0.5276↑ 0.6291↓ 0.0764↑ 
LA*AA*EPA*DHA 0.0246↓* 0.8641↓ 0.9194↑ 0.5389↑ 0.5631↑ 
‘*’ indicates significant effect at confidence level of 95% 
‘↑’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is higher than that without 
fatty acids; 
‘↓’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is lower than that without 
fatty acids 
 
Table 3.4 and Figure 3.2 show that the presence of AA significantly increases the production of PGE2, 
6-keto-PGF1α, PGE3 and Δ17-6-keto-PGF1α. The concentration of LTB4 is also slightly increased by AA, but 
its effect is not significant. Increase of PGE2, 6-keto-PGF1α and LTB4 indicates that during the incubation 
period, AA is incorporated into the cell membrane resulting in the releasing of AA into the cells and the 
synthesis of AA-derived eicosanoids The high levels of PGE2 and 6-keto-PGF1α compared to the low levels 
of LTB4 produced after exposing the cells to AA, are indicative that the added ω-6 PUFA is basically 
enrolled in COX pathway instead of LOX pathway.  The production of EPA metabolites, PGE3 and 
Δ17-6-keto-PGF1α, are also increased after exposing the cells to AA. Although, it was not expected the AA 
could have an influence on the aforementioned EPA metabolites, some researchers has already demonstrated 
that the presence of AA can stimulate in some degree the production of Δ17-6-keto-PGF1α in human 
endothelial cells
219
. In addition, increased levels of EPA-metabolites have also been observed in skin cells 
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from dogs fed n-6/n-3 diet ratios of 5/1 and 10/1
220
.  
Production of LTB4 is enhanced either by the presence of EPA or DHA. This confirms that EPA and 
DHA are incorporated into the by-layer phospholipid cell membrane after releasing AA in a dose- and 
time-dependent manner
221,222
. At the first 24 h, EPA and DHA are incorporated into the cell membrane at the 
expense of AA which is released and converted into AA-derived eicosanoids. The significance of EPA and 
DHA in the production of LOX metabolites compared to COX metabolites could be explained in terms of 
the activation energy of both enzymes (COX and LOX). For instance, if the activation energy of LOX were 
lower than that of COX, then it would be expected that the reaction rate of the former enzyme would be 
larger than of the latter enzyme and a higher production of LOX metabolites compared to COX metabolites 
would be observed
223
.  Unfortunately, this kind of measurements requires another type of experimental set 
up that was not considered at the time of designing the present experiments. 
LA reduces the production of Δ17-6-keto-PGF1α significantly (Table 3.4, Figure 4.2). The production of 
PGE3 and all the AA-derived metabolites are slightly affected by the exposure of salmon liver cells to LA. 
The former and the latter revealed some non-significant increased and decreased production of eicosanoids 
respectively (Table 3.4, Figure 4.2). It is possible that LA could form some AA (as indicated in Figure 1.2) 
which in turn replaces EPA in the cell membrane. The released EPA causes a decreasing in the levels of all 
the AA-metabolites due to the activation of the COX-pathways of EPA through the PGH3 synthase. It is 
well-known that PGH3 synthase is a common substrate for the production of both Δ17-6-keto-PGF1α and 
PGE3. The synthesis of Δ17-6-keto-PGF1α is possible through a multiple step mechanism where several 
chemical compounds are involved while the formation of PGE3 requires a less complex mechanism. 
Consequently, the observed reduction of Δ17-6-keto-PGF1α and increase of PGE3 could be explained as a 
result of spending PGH3 synthase in the formation of latter instead of the former. Perhaps, it would be 
advisable to measure the levels of PGI3 which is the precursor of Δ17-6-keto-PGF1α to determine effectively 
whether or not the PGH3 synthase has more affinity towards the production of the prostaglandin rather than 
the prostacyclin. 
One interesting finding is that both AA and EPA increase the production of five out of the seven 
eicosanoids studied in the present investigation. However, when they are present in medium at the same 
concentration, their combined effect remarkably decrease the production of LTB4 and slightly increase the 
production of all the COX-metabolites.  The interaction EPA×DHA decreases the production of LTB4 
which is also opposite to the individual effect of EPA or DHA indicating perhaps  that the ratio between 
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different PUFAs is a relevant aspect that should be evaluated when studying their impact on the on the 
production of eicosanoids
1
.  
Usually, high-order interactions are negligible. However, the significance of the interactions 
LA×EPA×DHA and LA×AA×EPA×DHA in Table 3.4 could be related to the incorporation and releasing of 
PUFAs. However, these results should be confirmed by introducing more replicates or perhaps by proposing 
a different experimental design. 
3.4 Conclusions 
In this chapter, the validated SPE-HPLC-MS/MS method was used to analyze the levels of eicosanoids 
released in cL-15 medium by salmon liver cells exposed to different combination of PUFAs. The present 
results seems to confirm the observations of Calder
222
  who has recently pointed out  that the actions of 
ω-6 and ω-3 PUFAs and their derivatives on inflammatory processes involve more complex mechanisms 
than previously recognized. Besides the availability of PUFAs, there are many other factors affecting the 
amount and type of the synthesized eicosanoids. 
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4. Application of the method to salmon head kidney cells 
4.1 Experimental 
4.1.1 Reagents 
NaCl-EDTA buffer was prepared by dissolving 9 g NaCl and 7 g of EDTA in 1 L of H2O and adjusting 
pH to 7.2. 
Stock isotonic Pecoll (SIP) was prepared by mixing 10 mL of 1.5 M NaCl with 90 mL of Percoll.  
From NaCl-EDTA buffer and SIP, 1.06 g/ml (21 ml SIP and 29 ml Buffer) and 1.08 g/ml (29 SIP and 21 
Buffer) of Percoll gradients were prepared and then 10 mL of 1.06 gradient was added slowly to 10 mL of 
1.08 gradient making sure these two phases were not mixed. The mixed Percoll gradients were used for cell 
isolation. 
4.1.2 Isolation of cells 
For each fish, the head kidneys were directly sampled and added PBS and then squeezed through a 40 
uM Falcon cell strainer. The cells were transferred to tubes and centrifuged in a Hettich Zentrifugen, 320 R, 
at 400 g, 5 min, and 4 °C. Cell pellets were resuspended in PBS and layered carefully on top of equal 
amounts of diluted Percoll in densities 1.08 g/mL and 1.06 g/mL. The tubes were centrifuged at 800 g, 30 
min, at room temperature. The cell layer in the interface containing the head kidney leukocytes was 
collected and the cells were pelleted by centrifugation, 400 g, 4 °C, and 5 min. An additional washing step in 
PBS was performed. In addition the cells were counted. 
4.1.3 Cell culture 
1.72×10
6
 head kidney cells were added to each well and different combinations of fatty acids were 
added according to 2
4
 -factorial design as the same with liver cells. These cultures were also incubated at 
9 °C in the incubator device. After 24h, suspensions were first centrifuged at 3200 rpm, 6 °C for 6 min and 
then the supernatant were collected carefully and stored at -80 °C until the analysis by HPLC-MS/MS. 
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Table 4.1 Concentrations in ng/ml of various eicosanoids released in cL-15 medium by salmon head kidney cells after 
exposure to different PUFAs. 
  LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA+AA+EPA+DHA 
1.1 1.032 0.725 11.495 0.305 31.152 
1.2 0.902 0.924 17.876 0.584 3.294 
1.3 2.558 0.858 0.019 0.931 6.303 
LA+AA+EPA 
2.1 2.078 0.838 1.015 0.534 2.748 
2.2 1.712 0.763 1.066 0.486 4.864 
2.3 2.709 1.024 2.853 1.301 19.079 
LA+AA+DHA 
3.1 1.296 1.309 1.066 0.966 1.895 
3.2 1.157 0.896 0.023 1.010 0.061 
3.3 2.086 1.393 1.149 1.124 1.034 
LA+AA 
4.1 0.990 0.855 0.786 0.399 1.710 
4.2 0.545 1.308 0.044 0.528 0.082 
4.3 0.991 1.095 0.089 1.196 0.106 
LA+EPA+DHA 
5.1 0.477 0.045 1.443 0.916 2.677 
5.2 0.306 0.037 2.317 0.390 3.518 
5.3 0.792 0.166 9.929 1.677 5.746 
LA+EPA 
6.1 0.224 0.051 2.793 0.465 3.295 
6.2 0.296 0.037 2.012 0.357 5.822 
6.3 0.647 0.954 16.391 13.736 19.739 
LA+DHA 
7.1 0.260 0.022 5.821 0.467 3.693 
7.2 0.266 0.019 3.298 0.691 2.651 
7.3 0.182 0.051 6.880 1.053 1.852 
LA 
8.2 0.025 0.012 1.778 0.256 1.186 
8.2 0.031 0.019 3.160 0.215 4.748 
8.3 0.832 0.164 3.434 1.410 3.460 
AA+EPA+DHA 
9.1 2.057 1.025 10.560 0.531 27.114 
9.2 0.260 0.022 16.146 0.467 39.729 
9.3 2.883 0.885 53.727 1.214 68.589 
AA+EPA 
10.1 1.241 0.812 17.846 0.329 52.346 
10.2 1.103 0.993 11.275 0.408 33.132 
10.3 3.296 1.036 29.956 1.624 28.281 
AA+DHA 
11.1 1.101 1.004 21.904 0.372 35.263 
11.2 0.850 0.836 21.170 0.298 38.661 
11.3 2.963 1.376 32.968 1.693 54.500 
AA 
12.1 1.187 1.423 25.834 0.408 61.174 
12.2 0.465 1.525 8.921 0.952 42.691 
12.3 2.517 1.272 48.918 1.852 53.586 
EPA+DHA 
13.1 0.313 0.034 1.546 0.134 7.897 
13.2 0.348 0.030 2.996 0.328 6.509 
13.3 0.191 0.093 3.680 1.122 6.359 
EPA 
14.1 0.395 0.055 1.451 0.338 8.481 
14.2 0.237 0.056 1.403 0.267 9.566 
14.3 0.411 0.142 3.445 1.694 15.453 
DHA 
15.1 0.021 0.022 1.229 0.204 3.731 
15.2 0.039 0.020 2.370 0.254 2.707 
15.3 0.141 0.152 7.661 0.910 6.970 
with ETOH 
16.1 0.055 0.028 4.001 0.318 6.816 
16.2 0.075 0.026 4.182 0.242 4.011 
16.3 0.482 0.242 8.850 2.203 9.253 
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4.2 Results and discussion 
The studied resolvins released in cL-15 medium by salmon head kidney cells were also not detected 
(similar results to the previous section by using salmon liver cells). The results showed in Table 4.2 and 
Figure 4.1 reveal that LA reduces the production of Δ17-6-keto-PGF1α and 6-keto-PGF1α significantly. The 
production of PGE3 is slightly increased while the remaining eicosanoids are not affected. The observed 
production trends for Δ17-6-keto-PGF1α and PGE3 have been already explained in the previous chapter, 
while the decreasing levels 6-keto-PGF1α could be interpreted as a significant reduction of AA which is 
incorporated into the cell membrane with the subsequent releasing of EPA. The results for AA (Table 4.2, 
Figure 4.1) are similar to those reported for salmon liver cells (Table 3.4, Figure 3.2) except that the 
production of PGE3 is unaffected.  
 
Table 4.2 Multifactor ANOVA results with the significant effects (P- values) for the impact of PUFAs on the 
production of various eicosanoids by salmon head kidney cells. 
 LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA 0.9599↑ 0.7789↑ 0.0004↓* 0.3642↑ 0.0000↓* 
AA 0.0000↑* 0.0000↑* 0.0006↑* 0.4726↓ 0.0000↑* 
EPA 0.1062↑ 0.0392↓* 0.9020↑ 0.4312↑ 0.2591↑ 
DHA 0.9897↑ 0.0934↓ 0.5685↑ 0.3270↓ 0.6282↓ 
LA*AA 0.4676↓ 0.5826↓ 0.0001↓* 0.3095↓ 0.0000↓* 
LA*EPA 0.6420↑ 0.2190↑ 0.2319↑ 0.3361↑ 0.1042↑ 
LA*DHA 0.9119↑ 0.3791↑ 0.7980↑ 0.5867↓ 0.6980↑ 
AA*EPA 0.4732↑ 0.0024↓* 0.8203↑ 0.2811↓ 0.7676↓ 
AA*DHA 0.8872↑ 0.7144↓ 0.4912↑ 0.3642↑ 0.4614↑ 
EPA*DHA 0.3625↓ 0.5207↓ 0.4768↑ 0.3957↓ 0.4958↑ 
LA*AA*EPA 0.6617↑ 0.9302↓ 0.6655↑ 0.3305↓ 0.1211↑ 
LA*AA*DHA 0.8142↓ 0.0882↑ 0.8972↑ 0.4523↑ 0.7294↑ 
LA*EPA*DHA 0.6072↓ 0.4435↓ 0.6472↓ 0.2978↓ 0.4414↓ 
AA*EPA*DHA 0.2158↓ 0.8435↑ 0.3445↑ 0.4592↑ 0.1695↑ 
LA*AA*EPA*DHA 0.5063↓ 0.9285↑ 0.7862↑ 0.4610↑ 0.6472↓ 
‘*’ indicates significant effect at confidence level of 95% 
‘↑’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is higher than that without  
fatty acids; 
‘↓’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is lower than that without 
fatty acids 
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The addition of EPA or DHA does not reveal any significant effect on the production of LTB4, PGE3, 
6-keto-PGF1α and Δ17-6-keto-PGF1α. However, the production of PGE2 is markedly reduced by either EPA 
or DHA, possibly due to the released of AA from the membrane which in term is engaged in the LOX 
pathway rather than the COX. This observation seems to be supported by the slightly increased levels of 
LTB4 after the addition of EPA.  
The combined effect LA×AA is similar to the effect of pure LA, while the effect of AA×EPA is similar 
to the effect of pure EPA. The observed similarity could suggest similar production mechanisms. 
4.3 Conclusions 
In general, the results after exposing salmon head kidney cells to pure or combined LA, AA, EPA and 
DHA were similar to those reported for salmon liver cells. The main differences with respect to the previous 
chapter were the decreased production of PGE2 (Table 4.2, Figure 4.1) after exposing the salmon head 
kidney cells to pure EPA. These observations could indicate that the two types of fish cells has the similar 
metabolism of PUFAs. 
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5. Application of the method to human umbilical vein endothelial cells  
In the previous two chapters, the method is applied to two types of fish cells. There is slight 
difference for the effect of PUFAs on the production of eicosanoids in different types of cells, but in 
general, they are almost the same. In this chapter, the type of cells is changed from fish to human, 
and the effects of PUFAs on human cells are investigated. 
5.1 Experimental 
5.1.1 Reagents 
Complete EBM-2 medium containing EBM
TM
-2 basal medium supplemented with 0.1 % 
Heparin, 0.1 % R
3
-IGF-1, 0.1 % ascorbic acid, 0.04 % Hydrocortisone, 0.4 % h-FGF-B, 0.1 % 
h-EGF, 0.1 % GA-1000 and 2 % FBS. 
5.1.2 Cell culture 
Human umbilical vein endothelial cells (HUVEC) were bought from Sigma-Aldrich and 
incubated in culture plate with complete EBM-2 medium. Once the number of cells reached 10
5
 
cells/well, the medium was removed. Different fatty acids, which were first attached to FBS and then 
dissolved in EBM-2 medium, were added according to 2
4
-full factorial design. Cultures were 
incubated at 37 °C in humidified atmosphere of 95% air and 5% CO2. After 24 h, the supernatant 
were collected and stored at -80 °C until the analysis by HPLC-MS/MS. 
5.2 Results and discussion 
Resolvins are also not detected in HUVEC. Table 5.1 shows the concentrations of the other five 
eicosanoids. The results of multi-factor ANOVA and LSD test are shown in Table 5.2 and Figure 5.1 
respectively. 
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Table 5.1 Concentrations in ng/ml of various eicosanoids released in EBM-2 medium by HUVEC after exposure to 
different PUFAs 
  LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA+AA+EPA+DHA 
1.1 11.190 4.510 2.797 2.845 9.449 
1.2 9.115 3.023 5.187 2.332 6.670 
1.3 4.281 3.885 4.503 2.605 10.204 
LA+AA+EPA 
2.1 2.778 9.870 4.787 2.858 15.033 
2.2 3.010 8.738 4.069 3.056 9.749 
2.3 3.315 9.592 2.052 2.859 5.099 
LA+AA+DHA 
3.1 8.509 6.369 1.661 2.804 7.264 
3.2 9.517 5.613 2.422 2.548 3.267 
3.3 4.875 5.973 3.326 3.766 7.590 
LA+AA 
4.1 1.610 17.206 2.653 5.659 5.263 
4.2 4.177 13.345 3.327 4.242 5.796 
4.3 2.567 6.076 2.004 2.883 6.611 
LA+EPA+DHA 
5.1 4.887 0.254 0.742 0.652 1.110 
5.2 4.931 0.296 0.605 0.648 2.964 
5.3 5.809 0.308 1.157 0.343 4.387 
LA+EPA 
6.1 6.393 0.775 2.721 0.889 3.184 
6.2 1.200 0.318 1.627 0.964 3.549 
6.3 1.801 0.426 1.573 0.779 4.838 
LA+DHA 
7.1 0.936 0.173 0.466 0.319 0.946 
7.2 1.965 0.151 0.805 0.341 1.824 
7.3 1.633 0.166 1.710 0.385 2.843 
LA 
8.2 0.771 0.354 1.649 0.315 1.166 
8.2 0.595 0.399 0.956 0.331 2.167 
8.3 0.457 0.376 1.424 0.465 3.927 
AA+EPA+DHA 
9.1 6.110 4.151 1.436 2.968 5.500 
9.2 5.548 9.890 1.943 4.074 6.853 
9.3      
AA+EPA 
10.1 4.081 20.468 2.689 2.951 26.638 
10.2 1.147 20.077 3.193 6.307 31.578 
10.3 3.535 19.056 3.019 4.530 17.796 
AA+DHA 
11.1 3.153 1.087 1.261 2.102 8.591 
11.2 3.581 1.467 0.719 3.692 6.776 
11.3 3.053 5.116 1.286 3.306 7.040 
AA 
12.1 0.856 18.788 5.248 10.791 56.405 
12.2 2.237 29.011 6.776 7.396 34.969 
12.3 1.393 16.155 4.027 6.430 31.214 
EPA+DHA 
13.1 1.846 0.243 0.293 0.857 0.511 
13.2 3.225 0.317 0.465 0.616 0.914 
13.3 2.142 0.273 0.326 0.372 0.698 
EPA 
14.1 1.677 0.427 0.660 0.900 1.603 
14.2 0.738 0.379 1.407 1.277 1.698 
14.3 0.999 0.360 0.967 0.948 3.778 
DHA 
15.1 0.290 0.255 0.245 0.492 0.636 
15.2 0.534 0.203 1.118 0.343 2.290 
15.3 0.824 0.165 0.616 0.355 1.460 
with ETOH 
16.1 0.177 0.163 0.346 0.273 1.660 
16.2 0.154 0.211 0.389 0.411 1.812 
16.3 0.207 0.304 0.574 0.458 1.710 
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Table 5.2 Multifactor ANOVA results with the significant effects (P- values) for the impact of PUFAs on the 
production of various eicosanoids by HUVEC 
 LTB4 PGE2 6-keto-PGF1α PGE3 Δ17-6-keto-PGF1α 
LA 0.0002↑* 0.0022↓* 0.0127↑* 0.0021↓* 0.0001↓* 
AA 0.0000↑* 0.0000↑* 0.0000↑* 0.0000↑* 0.0000↑* 
EPA 0.0003↑* 0.7969↓ 0.3454↑ 0.1125↓ 0.4411↓ 
DHA 0.0000↑* 0.0000↓* 0.0002↓* 0.0002↓* 0.0000↓* 
LA*AA 0.5716↑ 0.0018↓* 0.6251↓ 0.0044↓* 0.0000↓* 
LA*EPA 0.9474↑ 0.1743↓ 0.0105↑* 0.5701↑ 0.0131↑* 
LA*DHA 0.0594↑ 0.0019↑* 0.0082↑* 0.0259↑* 0.0000↑* 
AA*EPA 0.2245↓ 0.6711↓ 0.9364↑ 0.0032↓* 0.2255↓ 
AA*DHA 0.0060↑* 0.0000↓* 0.0628↓ 0.0016↓* 0.0000↓* 
EPA*DHA 0.3099↑ 0.2703↑ 0.2407↑ 0.0453↑* 0.2755↑ 
LA*AA*EPA 0.0628↓ 0.1723↓ 0.0181↑* 0.4623↑ 0.0415↑* 
LA*AA*DHA 0.2514↑ 0.0014↑* 0.0003↑* 0.0296↑* 0.0000↑* 
LA*EPA*DHA 0.8730↓ 0.3721↓ 0.2097↓ 0.1412↓ 0.1496↓ 
AA*EPA*DHA 0.8574↓ 0.2560↑ 0.0036↑* 0.0082↑* 0.1470↑ 
LA*AA*EPA*DHA 0.7480↓ 0.3568↓ 0.1776↓ 0.1104↓ 0.1073↓ 
‘*’ indicates significant effect at confidence level of 95% 
‘↑’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is higher than that without  
fatty acids; 
‘↓’ indicates  the mean concentration of corresponding eicosanoid with the addition of fatty acids  is lower than that without 
fatty acids 
 
In general, HUVEC are more sensitive than fish cells. Hence, the results revealed more significant 
effects. LA significantly decreases the production of EPA-derived eicosanoids and PGE2, while it increases 
the production of LTB4 and 6-keto-PGF1α. This result may indicate that during the incubation period, LA is 
incorporated into cell membranes releasing some ω-6 fatty acids and consequently the production of 
EPA-derived eicosanoids is reduced and AA-derived eicosanoids enhanced. However, the production of 
PGE2 which is one of COX product of AA is decreased indicating that prostacyclin may be the major 
product of COX in this case. 
The effects of AA and EPA have the similar behavior with those in fish cells. DHA remarkably increases 
the levels of eicosanoids from LOX pathway and significantly reduces the levels of eicosanoids from COX. 
These observations could indicate that DHA is incorporated into cell membrane during the incubation period 
by releasing AA which in turn is mainly enrolled in the LOX pathway. 
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The interactions LA×DHA, EPA×DHA and LA×AA×DHA increase the production of PGE2, PGE3, 
LTB4, 6-keto-PGF1α, Δ17-6-keto-PGF1α. It is evident that these interaction terms exhibit a behavior similar 
to single AA. The terms AA×DHA, LA×AA exhibit a similar behavior to pure DHA, increase the production 
of LTB4 and decrease the production of PGE2, PGE3, 6-keto-PGF1α and Δ17-6-keto-PGF1α. These similarities 
for the combined and pure PUFAs could indicate a similar metabolic fate.  The interactions LA×EPA and 
LA×AA×EPA bring about a mainly markedly increased on the production of the two ω-3 and ω-6 derived 
prostacyclins (Δ17-6-keto-PGF1α and 6-keto-PGF1α respectively).  
5.3 Conclusions 
It is evident from the results portrayed in the present section that human cells behave differently from 
salmon cells when exposed to the same set of pure or combined PUFAs. Considering that the analyzed 
salmon cells (head kidney and liver) exhibited a similar eicosanoid production behavior which was different 
from human cells, then it is possible to conclude that the metabolic fate of PUFAs is mainly dictated by the 
type of organism . 
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6. Conclusions and further prospectives 
In this thesis, a new SPE-HPLC-MS/MS method was firstly developed to determine 
simultaneously prostaglandins (PGE2, PGE3), leukotriene (LTB4), protacyclins (6-keto-PGF1α, 
Δ17-6-keto-PGF1α) and resolvins (RvD1 and RvD2) released in cL-15 and EBM-2 medium by fish 
and human cells respectively. The proposed method was optimized systematically and validated. The 
optimal concentrations of the various internal standards, defined as those where the response factors 
remain constant in the whole analytical range were determined using a Doehlert design.  
The method validation carried out by using the optimal concentrations of internal standards 
showed that the developed SPE-HPLC-MS/MS method was highly selective, precise, accurate with 
acceptable LOD (0.1-2 ng/ml) and LOQ (0.1-8 ng/ml).  
The validated method was successfully applied to analyze the levels of eicosanoids released into 
different culture media by fish and human cells exposed to different combination of PUFAs.  
It must be said that this work  is the first approach to compare the production of eicosanoids 
released into media by fish and human cells.  
The change trend of each eicosanoids in different types of cells are summarized in Table 6.1. In 
general, AA, one of the most studied PUFAs in the current literature due to its implication in various 
pathological processes, has the tendency to  increase  the production of PGE2, PGE3, LTB4, 
6-keto-PGF1α, Δ17-6-keto-PGF1α, and the addition of EPA markedly increased the production of LTB4 
in both fish and human cells. The behaviour of LA was similar towards the production of 
prostacyclin in fish cells. However, its behaviour was different when human cells were analyzed, 
indicating that the type and  production of eicosanoids are affected by both the avaiablity of fatty 
acids and type of cells.  
Finally, it must be said that several improvements could be introduced in future research aiming 
at study the impact of PUFAs on the production of eicosanoids. Firstly, it would be convenient to 
analyze RvD3 and RvD4 (detected in the present work but their identity not confirmed) considering 
that RvD1 and RvD2 were not released into the media by any types of the studied cells. Secondly, the 
cells could be incubated for a longer period of times since the incorporation and releasing of PUFAs 
in and from cell membranes is  time-dependent. Thirdly, the ratio between different ω-3 and ω-6 
PUFAs should be explored considering that the incorporation of PUFAs in the cell membrane is 
dose-dependent. 
Conclusions and further prospectives 
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Appendix I 
Statistical analysis to validate the recovery range (60-120%) for PGE3 and LTB4  
when the nominal concentration is 50 ng/ml 
z =
𝑥−𝑢
𝜎  
              f(z) =
1
√2𝜋
𝑒−
𝑧2
2  
 
% recovery 
expected  
concentrations(x) 
(ng/ml) 
z-values f(z) 
120 60 1.65 0.10 
18 59 1.54 0.12 
16 58 1.43 0.14 
114 57 1.32 0.17 
112 56 1.21 0.19 
110 55 1.10 0.22 
108 54 0.99 0.24 
106 53 0.88 0.27 
104 52 0.77 0.30 
102 51 0.66 0.32 
100 50 0.55 0.34 
98 49 0.44 0.36 
96 48 0.33 0.38 
94 47 0.22 0.39 
92 46 0.11 0.40 
90 45 0.00 0.40 88 44 -0.11 0.40 
86 43 -0.22 0.39 
84 42 -0.33 0.38 
82 41 -0.44 0.36 
80 40 -0.55 0.34 
78 39 -0.66 0.32 
76 38 -0.77 0.30 
74 37 -0.88 0.27 
72 36 -0.99 0.24 
70 35 -1.10 0.22 
68 34 -1.21 0.19 
66 33 -1.32 0.17 
64 32 -1.43 0.14 
62 31 -1.54 0.12 
60 30 -1.65 0.10 
Mean (μ) 45   
Standard 
deviation 
(σ) 
9   
 
